Merck (MRK) EBIT Growth (3y) (2012 - 2026)
Powered by 
Analysis
Merck (MRK) EBIT Growth (3y) (2012 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 641.14 Bn | 620.38 Bn | 17.26 Bn | 7.09% |
| 2 | AbbVie | 451.04 Bn | 444.47 Bn | 12.70 Bn | 12.54% |
| 3 | Merck | 357.43 Bn | 350.29 Bn | 12.21 Bn | 51.64% |
| 4 | Novartis Ag | 266.73 Bn | 259.04 Bn | 11.24 Bn | 19.17% |
| 5 | Pfizer | 157.52 Bn | 145.82 Bn | 10.94 Bn | 7.73% |
| 6 | Sanofi | 52.14 Bn | 44.76 Bn | 10.79 Bn | -15.60% |
| 7 | Revolution Medicines | 42.88 Bn | 42.88 Bn | - | - |
| 8 | Incyte | 24.70 Bn | 20.16 Bn | 1.57 Bn | 53.28% |
| 9 | United Therapeutics | 21.47 Bn | 18.80 Bn | 683.80 Mn | 1.82% |
| 10 | Neurocrine Biosciences | 15.82 Bn | 15.43 Bn | 935.80 Mn | 27.21% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 51.64% |
| Mar 31, 2026 | -42.74% |
| Dec 31, 2025 | 30.20% |
| Sep 30, 2025 | 17.49% |
| Jun 30, 2025 | 0.45% |
| Mar 31, 2025 | 1.76% |
| Dec 31, 2024 | 6.32% |
| Sep 30, 2024 | -6.57% |
| Jun 30, 2024 | 55.32% |
| Mar 31, 2024 | 30.58% |
| Dec 31, 2023 | 40.47% |
| Sep 30, 2023 | 33.89% |
| Jun 30, 2023 | -61.26% |
| Mar 31, 2023 | -1.47% |
| Dec 31, 2022 | 58.50% |
| Sep 30, 2022 | 18.98% |
| Jun 30, 2022 | 13.16% |
| Mar 31, 2022 | 19.60% |
| Dec 31, 2021 | 9.62% |
| Sep 30, 2021 | 24.54% |